Clinical Trial Detail

NCT ID NCT02359019
Title Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy
Recruitment Unknown status
Gender both
Phase Phase II
Variant Requirements No
Sponsors Barbara Ann Karmanos Cancer Institute
Indications

lung small cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.